毒素A用于改善面部伤口愈合的化品结果:系统性审查,元分析和剂量反应评估
Thamer M AlBilasi1,2, Reem Mansour Kublan Alkublan3, Alanoud S Suayb3
1Department of Otolaryngology and Head and Neck Surgery, Aliman Hospital, Riyadh First Healthcare Cluster, Riyadh, Saudi Arabia.
The Journal of craniofacial surgery
|September 24, 2025
概括
毒素A (BTX-A) 显著改善了面部伤口愈合,减少了痕宽度和改善了化品的结果. 基于证据的5至15U/cm的剂量为面部伤口管理提供了最佳的益处风险比.
科学领域:
- 整形外科 整形外科 整形外科
- 皮肤病学 皮肤病学
- 再生医学是一种再生医学.
背景情况:
- 面部伤口愈合经常导致不良痕,影响美学和心理健康.
- 毒素A (BTX-A) 正在探索其在愈合过程中通过减少肌肉张力来减轻痕的潜力.
研究的目的:
- 系统地审查和元分析BTX-A在治疗面部伤口中的有效性和安全性.
- 确定面部伤口护理中BTX-A的最佳剂量策略.
主要方法:
- 在2025年5月15日之前,按照PRISMA 2020指南进行系统的文献搜索.
- 包括15项研究 (607名参与者),比较BTX-A与面部伤口愈合的对照.
- 主要结局:视觉模拟量表 (VAS) 评分和痕宽度;次要结局:温哥华痕量表,患者满意度,不良事件;剂量反应的元回归.
主要成果:
- BTX-A显著改善了VAS分数 (SMD 0.87),并将痕宽度减少了0.35毫米.
- 超回归显示出剂量反应关系,最佳疗效和安全性在5-15U/cm之间观察到.
- 在BTX-A和对照组之间,不良事件的发生率相似 (3.9%对3.4%),没有严重的并发症.
结论:
- 在面部伤口愈合过程中,BTX-A有效且安全地改善了美容效果.
- 基于证据的5-15U/cm的剂量提供了最佳的益处风险比.
- 对于高可见性区域的伤口,特别是较长的伤口,BTX-A显示出有利的成本效益.
相关概念视频
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.1K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.1K
Skeletal Muscle Relaxants: Therapeutic Uses
847
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
847


